AIMS/HYPOTHESIS: The primary aim of this study was to determine whether the presence of one or more APOE epsilon4 alleles modifies the association between diabetes (defined by glucose > or =7 mmol/l or treatment) and cognitive function. METHODS: Diabetic status and APOE genotype interactions were assessed cross-sectionally for 826 community-dwelling, stroke-free, non-demented individuals (526 non-diabetic non-APOE epsilon4 carriers, 174 non-diabetic APOE epsilon4 carriers, 87 diabetic APOE epsilon4 non-carriers, 39 diabetic APOE epsilon4 carriers) ranging in age from 50 to 98 years. Cognitive function was assessed using the Mini-Mental State Examination (MMSE), the similarities subtest from the Wechsler Adult Intelligence Scale, and four composite scores derived from 17 additional neuropsychological tests. Multiple linear regression analyses were employed to relate diabetes and APOE genotype to cognitive performance and to examine the interaction between these two risk factors as they relate to cognitive performance. Multiple cardiovascular disease risk factors were statistically controlled. RESULTS: With adjustment for age, education, sex, race/ethnicity and APOE genotype, performance level was lower for the diabetic than for the non-diabetic group for the MMSE, the similarities subtest and each of the cognitive composites with the exception of the verbal memory composite. Interactions (p < 0.05) between diabetes and APOE genotype were found for all but the visual-spatial memory/organisation composite. The negative association between diabetes and cognitive performance was of a higher magnitude for individuals who carry one or more APOE epsilon4 alleles. Results were similar with additional adjustment for cardiovascular disease and associated risk factors. CONCLUSIONS/ INTERPRETATION: The presence of one or more APOE epsilon4 alleles modifies the association between diabetes and cognitive function.
AIMS/HYPOTHESIS: The primary aim of this study was to determine whether the presence of one or more APOE epsilon4 alleles modifies the association between diabetes (defined by glucose > or =7 mmol/l or treatment) and cognitive function. METHODS:Diabetic status and APOE genotype interactions were assessed cross-sectionally for 826 community-dwelling, stroke-free, non-demented individuals (526 non-diabetic non-APOE epsilon4 carriers, 174 non-diabeticAPOE epsilon4 carriers, 87 diabeticAPOE epsilon4 non-carriers, 39 diabeticAPOE epsilon4 carriers) ranging in age from 50 to 98 years. Cognitive function was assessed using the Mini-Mental State Examination (MMSE), the similarities subtest from the Wechsler Adult Intelligence Scale, and four composite scores derived from 17 additional neuropsychological tests. Multiple linear regression analyses were employed to relate diabetes and APOE genotype to cognitive performance and to examine the interaction between these two risk factors as they relate to cognitive performance. Multiple cardiovascular disease risk factors were statistically controlled. RESULTS: With adjustment for age, education, sex, race/ethnicity and APOE genotype, performance level was lower for the diabetic than for the non-diabetic group for the MMSE, the similarities subtest and each of the cognitive composites with the exception of the verbal memory composite. Interactions (p < 0.05) between diabetes and APOE genotype were found for all but the visual-spatial memory/organisation composite. The negative association between diabetes and cognitive performance was of a higher magnitude for individuals who carry one or more APOE epsilon4 alleles. Results were similar with additional adjustment for cardiovascular disease and associated risk factors. CONCLUSIONS/ INTERPRETATION: The presence of one or more APOE epsilon4 alleles modifies the association between diabetes and cognitive function.
Authors: Natalie Galanina; Vijaya Surampudi; Daniela Ciltea; Sant P Singh; Lawrence C Perlmuter Journal: Exp Aging Res Date: 2008 Apr-Jun Impact factor: 1.645
Authors: C H Kawas; M M Corrada; R Brookmeyer; A Morrison; S M Resnick; A B Zonderman; D Arenberg Journal: Neurology Date: 2003-04-08 Impact factor: 9.910
Authors: Kerryn E Pike; Greg Savage; Victor L Villemagne; Steven Ng; Simon A Moss; Paul Maruff; Chester A Mathis; William E Klunk; Colin L Masters; Christopher C Rowe Journal: Brain Date: 2007-10-10 Impact factor: 13.501
Authors: Fumiko Irie; Annette L Fitzpatrick; Oscar L Lopez; Lewis H Kuller; Rita Peila; Anne B Newman; Lenore J Launer Journal: Arch Neurol Date: 2008-01
Authors: Fan Liu; Luba M Pardo; Maaike Schuur; Pascual Sanchez-Juan; Aaron Isaacs; Kristel Sleegers; Ingrid de Koning; Irina V Zorkoltseva; Tatiana I Axenovich; Jacqueline C M Witteman; A Cecile J W Janssens; John C van Swieten; Yurii S Aulchenko; Ben A Oostra; Cornelia M van Duijn Journal: Neurobiol Aging Date: 2008-11-11 Impact factor: 4.673
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Katherine J Bangen; Jayandra J Himali; Alexa S Beiser; Daniel A Nation; David J Libon; Caroline S Fox; Sudha Seshadri; Philip A Wolf; Ann C McKee; Rhoda Au; Lisa Delano-Wood Journal: J Alzheimers Dis Date: 2016-07-06 Impact factor: 4.472
Authors: Lance A Johnson; Reid H J Olsen; Louise S Merkens; Andrea DeBarber; Robert D Steiner; Patrick M Sullivan; Nobuyo Maeda; Jacob Raber Journal: Neurobiol Dis Date: 2014-01-09 Impact factor: 5.996
Authors: H Wersching; K Guske; S Hasenkamp; C Hagedorn; S Schiwek; S Jansen; V Witte; J Wellmann; H Lohmann; K Duning; J Kremerskothen; S Knecht; E Brand; A Floel Journal: Neuropsychopharmacology Date: 2011-02-23 Impact factor: 7.853
Authors: Kathleen M Hayden; Sarah A Gaussoin; Jaimie C Hunter; JoAnn E Manson; Bonnie C Sachs; Aladdin H Shadyab; Hilary A Tindle; Yasmin Mossavar-Rahmani; Khyobeni Mozhui; Beverly M Snively; Stephen R Rapp; Susan M Resnick Journal: Int J Geriatr Psychiatry Date: 2019-08-22 Impact factor: 3.485
Authors: Katherine J Bangen; Alexa Beiser; Lisa Delano-Wood; Daniel A Nation; Melissa Lamar; David J Libon; Mark W Bondi; Sudha Seshadri; Philip A Wolf; Rhoda Au Journal: J Stroke Cerebrovasc Dis Date: 2013-04-17 Impact factor: 2.136
Authors: Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Mary Sano; Rachel Preiss; Keren Koifman; Hadas Hoffman; Jeremy M Silverman; Michal Schnaider Beeri Journal: Eur Neuropsychopharmacol Date: 2014-05-14 Impact factor: 4.600